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Abstracts
Gregory L. Moneta, MD, Section EditorDisparity in Outcomes of Surgical Revascularization for Limb Salvage:
Race and Gender are Synergistic Determinants of Vein Graft Failure
and Limb Loss
Nguyen LL, Hevelone N, Rogers SO, et al. Circulation 2009;119:123-30.
Conclusion: Female gender and black race are risk factors for adverse
events after vein bypass surgery for limb salvage.
Summary: This article represents another of the many interesting post
hoc analyses derived from the PREVENT III, a multicenter clinical trial of
patients undergoing vein bypass for critical limb ischemia (J Vasc Surg
2006;43:742-51). The PREVENT III database represents the largest pro-
spective cohort of patients who underwent surgical treatment for critical
limb ischemia. The database includes 1404 lower extremity vein graft
operations performed for critical limb ischemia at 83 North American
centers. The patients had intensive ultrasound surveillance of the bypass
graft and clinical follow-up for 1 year.
This particular analysis was designed to examine the interactions of race
and gender as they affect graft patency, limb salvage, and mortality. Propor-
tional hazards and propensity scoring was used to examine relationships of
patient demographics to relevant clinical end points. These included peri-
operative events and 1-year outcomes of graft patency, limb salvage, and
patient survival. Propensity score models adjusting for covariants that in-
cluded institution, comorbidities, technical factors, and adjunctive medica-
tions were used to examine associations between race, gender, and out-
comes.
The PREVENT III trial had 249 black patients (131 men and 118
women). Black men were at increased risk for early (30-day) graft failure
(hazard ratio [HR], 2.832; 95% confidence interval [CI], 1.393-5.759; P
.0004). This held true even when analysis was restricted to exclude high-risk
venous conduits. Black patients also had reduced secondary patency (HR,
1.49; 95% CI, 1.08-2.06; P  .016) and reduced limb salvage (HR, 2.02;
95% CI, 1.27-3.20; P  .003) at 1 year. Black women were the most
disadvantaged, with an increased risk of graft thrombosis (HR, 2.02 for
secondary patency; 95% CI, 1.27-3.20; P  .003) and an increased risk for
major amputation (HR, 2.38; 95% CI, 1.18-4.83; P  .016) at 1 year.
Perioperative mortality and 1-year mortality, however, were similar across
race and gender groups.
Comment: It has been previously suggested that African Americans
and women have poorer results with vascular surgery. The findings in this
study are therefore not all that surprising. The authors suggest the data raise
the possibility of an altered response to vein bypass surgery in there sub-
groups. It is certainly not obvious what this biologic response would be.
Nevertheless, the clinical implication is that African American women un-
dergoing vein graft bypass surgery are a particularly high-risk group that may
benefit from very aggressive postoperative surveillance and medical manage-
ment.
General Anesthesia Versus Local Anesthesia for Carotid Surgery
(GALA): A Multicentre, Randomised Controlled Trial
GALA Trial Collaborative Group. Lancet 2008;372:2132-42.
Conclusion: There is no definite difference in outcomes between
general and local anesthesia for carotid surgery.
Summary: Whether carotid endarterectomy under local or general
anesthesia results in a more favorable outcome is a topic of considerable
debate. The General Anesthesia Versus Local Anesthesia for Carotid Surgery
(GALA) trial sought to address the efficacy of local vs general anesthesia in
the prevention of complications of carotid surgery. This was a parallel group,
multicenter, randomized controlled trial of 3526 patients with symptomatic
or asymptomatic carotid stenosis. The patients were derived from 95 centers
in 24 countries. Study participants were randomly assigned to surgery under
general (n  1763) or local (n  1773) anesthesia. The primary outcome
end point was the proportion of patients with stroke (including retinal
infarction), death between randomization and 30 days after surgery, or
myocardial infarction. Analysis was on an intention to treat basis.
The general anesthesia patients sustained 84 (4.8%) outcome events
and the local anesthesia patients had 80 (4.5%). Overall, three events per
1000 patients treated were prevented with local anesthesia (95% confidence
interval, -11 to 17) with a risk ratio of 0.94 (95% confidence interval,
0.70-1.27). There were no differences between those patients undergoing
surgery with local vs general anesthesia with respect to quality of life, length
of hospital stay, or the primary outcome in prespecified subgroups stratified
for age, contralateral carotid occlusion, and baseline surgical risk.Comment: The trial failed to show a convincing difference between
general and local anesthesia with respect to outcomes after carotid surgery.
1626There were no significant differences with regard to perioperative stroke,
myocardial infarction, or death. The results are consistent with other clinical
trials evaluating major surgical procedures that have also failed to show a
convincing benefit for local or regional anesthesia (BMJ 2000;323:1493 and
Lancet 2002;359:1276-82). The surgeon and the anesthesiologist as a team
should use whatever technique they are most comfortable with in perform-
ing carotid surgery.
Deep Vein Thrombosis of Lower Extremity: Direct Intraclot Injection
of Alteplase Once Daily with Systemic Anticoagulation—Results of
Pilot Study
Chang R, Chen CC, Kam A, et al. Radiology 2008;246:619-29.
Conclusion: Daily intraclot injection of a venous thrombus with
alteplase can be an alternative to continuous infusion thrombolytic therapy
for treatment of deep venous thrombosis (DVT).
Summary: An alternative to continuous infusion of lytic agents is to
intermittently lace the thrombus with a thrombolytic agent that binds to
fibrin in the clot and is rapidly cleared from the general circulation. This can
allow the thrombolytic agent to work at the site where it is needed but
minimize the duration of systemic exposure to the thrombolytic agent.
This study prospectively evaluated the outcome of patients with acute
DVT in the lower extremity treated with daily lacing of the thrombus with
alteplase. Alteplase has a high fibrin affinity and therefore continuous infu-
sion of the thrombolytic agent is not required. Twenty patients with first-
onset acute DVT were treated with direct daily lacing of the thrombus with
alteplase with amaximum daily dosage of 50mg/leg and amaximum of four
treatments. Catheters were left in place between treatments. Patients were
also systemically anticoagulated fully. Patients underwent ventilation perfu-
sion (V/Q) scans, which were performed before treatment and during
thrombolytic therapy.
The study comprised 13 men and 7 women, aged 18 to 79 years.
Antegrade blood flow was restored throughout the deep venous system in
16 patients (80%) during thrombolytic therapy. After 6 months of antico-
agulation, 18 patients (90%) had complete resolution of symptoms. There
was rapid clearance of circulating alteplase and recovery of plasminogen
activator inhibitor-1 levels by pharmacokinetic studies 2 hours after ter-
mination of alteplase treatment. A 40% incidence of pulmonary embolism
was documented by V/Q scanning before treatment and a 15% incidence of
asymptomatic pulmonary embolism during thrombolytic therapy. No clin-
ically important pulmonary embolism or serious bleeding occurred during
thrombolytic therapy. During the mean follow-up of 3.4 years, no post-
thrombotic syndrome or recurrent DVT developed in any patient.
Comment: The most obvious practical advantage of this approach is
that patients do not require intensive monitoring of a continuous infusion of
a thrombolytic agent. However, intermittent administration of alteplase
directly into the thrombus does require a substantial time commitment.
Procedure times for the first treatment of an uncomplicated iliofemoral DVT
were 1.5 hours. If there was extensive calf DVT, initial procedure times
could be doubled or almost tripled. Procedure times for subsequent treat-
ments are shorter because catheters are left in place after the initial treatment
and can be exchanged using standard guidewire techniques. Overall, it
appears if one has the catheter skills and time, intermittent administration of
a thrombolytic agent directly into the clot may be a viable alternative tomore
standard continuous infusion techniques.
Determinants of Systemic Vascular Function in Patients with Stable
Chronic Obstructive Pulmonary Disease
Eickhoff P, Valipour A, Kiss D, et al. Am J Resp Crit Care Med 2008;178:
1211-8.
Conclusion: Endothelium-dependent and endothelium-independent
vasodilation is impaired in patients with chronic obstructive pulmonary
disease (COPD).
Summary:COPD is an inflammatory lung disease; however, increasing
data suggest the inflammatory reaction associated with COPD is not re-
stricted to the lung. Patients with stable COPD had increased levels of
systemic inflammatory markers, such as C-reactive protein, compared with
controls. In addition, inflammation associated with COPD appears to in-
creases over time, and systemic inflammation associated with COPD in-
creases during acute exacerbations. Systemic inflammation also contributes
to the development of cardiovascular diseases. It has been observed that
there is an increased risk of cardiovascular morbidity and mortality in
